{"url_path":"/sec/aqst/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1398733/0001398733-26-000041-index.html","accession_number":"0001398733-26-000041","cik":"0001398733","ticker":"AQST","issuer_name":"Aquestive Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1398733/0001398733-26-000041-index.html","primary_entity_key":"0001398733","primary_entity_name":"Aquestive Therapeutics, Inc."},"word_count":118,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\nExhibit NumberDescription\n\n[99.1](q22026-ex991earningsrelease.htm)\nPress Release, dated August 11, 2026, announcing the Company’s reported financial results for the second quarter ended June 30, 2026 and providing an update on recent developments in its business.\n\n[99.2](q22026supplementalearnin.htm)\nAquestive Therapeutics, Inc. Q2 Earnings Supplemental Materials dated August 11, 2026.\n\n104Cover Page Interaction Data File (embedded within the Inline XBRL document)\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDated: August 11, 2026\nAquestive Therapeutics, Inc.\n\nBy:/s/ A. Ernest Toth, Jr\n\nName: A. Ernest Toth, Jr.\n\nTitle: Chief Financial Officer"}